Biogen Stock Based Compensation Over Time
| BIIB Stock | USD 159.83 2.14 1.36% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biogen Performance and Biogen Correlation. Biogen |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.06 | Revenue Per Share 66.122 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0499 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Stock Based Compensation Analysis
Compare Biogen Inc and related stocks such as Bristol Myers Squibb, AbbVie Inc, and Merck Company Stock Based Compensation Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | 890 M | 161 M | 154 M | 191 M | 213 M | 235 M | 205 M | 199 M | 221 M | 441 M | 779 M | 583 M | 457 M | 518 M | 262.8 M |
| ABBV | 156.7 M | 163 M | 187 M | 212 M | 241 M | 282 M | 353 M | 365 M | 421 M | 430 M | 753 M | 692 M | 671 M | 747 M | 428.3 M |
| MRK | (462.4 M) | 369 M | 335 M | 276 M | 278 M | 299 M | 300 M | 312 M | 348 M | 417 M | 475 M | 479 M | 541 M | 645 M | 346.8 M |
| GILD | 165 K | 192.4 M | 208.7 M | 252 M | 360 M | 382 M | 380 M | 638 M | 845 M | 636 M | 643 M | 635 M | 637 M | 795 M | 423.9 M |
| JNJ | 559 M | 621 M | 662 M | 728 M | 792 M | 874 M | 878 M | 962 M | 978 M | 977 M | 1 B | 1.1 B | 1.1 B | 1.2 B | 925.6 M |
| AMGN | (9 M) | 341 M | 362 M | 403 M | 408 M | 322 M | 311 M | 329 M | 311 M | 308 M | 330 M | 341 M | 401 M | 431 M | 249.8 M |
| PFE | 77.2 M | 419 M | 481 M | 523 M | 586 M | 669 M | 691 M | 840 M | 949 M | 718 M | 756 M | 1.2 B | 872 M | 525 M | 551.2 M |
| SNY | (23 M) | 238 M | 155 M | 200 M | 206 M | 206 M | 250 M | 263 M | 284 M | (119 M) | (7.4 B) | (108 M) | (234 M) | 283 M | 297.1 M |
| NVS | (591 M) | 790 M | 746 M | 730 M | 744 M | 773 M | 671 M | 683 M | 759 M | 758 M | 738 M | 736 M | 823 M | 865 M | 592.7 M |
| GSK | 179 M | 198 M | 220 M | 319 M | 332 M | 368 M | 319 M | 333 M | 360 M | 365 M | 381 M | 367 M | 346 M | 307 M | 335.4 M |
Biogen Inc and related stocks such as Bristol Myers Squibb, AbbVie Inc, and Merck Company Stock Based Compensation description
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.My Equities
My Current Equities and Potential Positions
| Biogen Inc | BIIB |
| Classification | Hedge Favorites |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 159.83
Check out Biogen Performance and Biogen Correlation. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Biogen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.